Nearly half a million people died from drug use in 2023. The United Nations now warns that the global drug crisis is entering a more dangerous phase. In turn, synthetic substances are edging out traditional plant based drugs across major markets worldwide.

The UN Office on Drugs and Crime, or UNODC, published its World Drug Report 2026 this month. Its findings paint a picture of a crisis that is both widening and deepening. An estimated 331 million people used illicit drugs in 2024. That figure marks a 34 per cent rise over the past decade, well ahead of population growth. Only part of that increase reflects better data collection, according to the report. In other words, the underlying scale of use has been growing steadily for years.

“The consequences are lethal,” wrote UNODC executive director Monica Juma in the report’s foreword. “These deaths are a reminder that the world drug problem remains, at its nucleus, a human challenge that affects lives, families and communities.”

A record global drug crisis takes shape

Cannabis remains the most widely used drug worldwide, with 256 million users. Opioids follow at 63 million, then amphetamines at 32 million. Meanwhile, cocaine production hit an all time high of 4,100 tonnes in 2024, more than four times the level recorded a decade earlier.

Yet it is the sheer novelty of what is now circulating that has alarmed researchers most. A record 755 new psychoactive substances turned up in 2024 alone. In fact, five times as many distinct drug types now appear in seizures compared with the period before 2000. Since 2014, international authorities have added 92 new substances to control schedules. Still, 118 fresh compounds appeared in 2024 alone. Regulation is struggling to keep pace with the chemistry now driving the global drug crisis.

“We have seen an unprecedented spike in new types of drugs on the market,” Juma told the report’s launch in Vienna. “Worryingly, some are more potent or dangerous than before.”

Synthetic drugs push the crisis into new territory

Nowhere is that shift clearer than in opioids. Fentanyl is roughly 50 times stronger than heroin and far cheaper to produce. As a result, it transformed North America’s drug supply within a decade. At its peak in 2023, it killed more Americans in a single year than the entire Vietnam War claimed. The United States is home to around 4 per cent of the world’s population. Yet it recorded some 110,000 overdose deaths that year, roughly a quarter of the global toll.

There are early signs of progress, though. Overdose deaths involving fentanyl fell by more than a third in the United States during 2024, and by 17 per cent in Canada. Overall, analysts credit a combination of shrinking supply, wider availability of the overdose reversal medication naloxone and expanded treatment access.

Even so, fentanyl’s successors are already circulating. Nitazenes are a class of synthetic opioids that can exceed fentanyl’s potency, and they have now turned up in 37 countries since 2019. In the United Kingdom, they have been linked to roughly 750 overdose deaths between June 2023 and August 2025. That is nearly three times the toll attributed to fentanyl there. Elsewhere, a newer class, orphines, has already surfaced in at least 14 countries.

Chloe Carpentier, the UNODC research chief who coordinated the report, said fentanyl’s rise is only the beginning. “The worry is really that synthetic opioids might replace heroin and lead to much more harm,” she said.

Disease, not overdose alone, drives the death toll

Of the 492,000 deaths attributed to drug use in 2023, only 172,500 were direct deaths, such as fatal poisonings. Instead, most people died more slowly, from infections contracted through needle use years or decades earlier.

Cirrhosis and liver disease linked to hepatitis C were the leading cause of drug related death. That accounted for 46 per cent of the total. In addition, HIV and AIDS accounted for a further 15 per cent, claimed among people living with both the virus and addiction. That toll has grown heavier amid a sharp decline in global HIV funding. An estimated 14.3 million people injected drugs in 2024. Nearly half of them were living with hepatitis C.

Two conflicts are redrawing the supply map

Political upheaval, more than any single enforcement strategy, has reshaped where the world’s drugs come from. Afghan opium production was once responsible for 80 per cent of the world’s illicit supply. It has since collapsed by 95 per cent, after the Taliban banned poppy cultivation. Production fell from 6,200 tonnes in 2022 to an estimated 296 tonnes in 2025. As a result, heroin prices in major destination markets have doubled in two years. UNODC now estimates that existing stockpiles could run dry before the end of 2026.

No single producer has filled the gap left behind. Myanmar has become the world’s largest opium source. Its rise reflects its own civil war, though, rather than any deliberate effort to replace Afghan supply. Researchers fear traffickers may turn further towards fentanyl, nitazenes and other synthetics. Such a shift would permanently alter illicit opioid markets and deepen the global drug crisis further still.

A second upheaval followed the fall of the Assad government in Syria in late 2024. That collapse unravelled a captagon trade researchers had valued in the billions of dollars annually. Since then, authorities have dismantled sixteen mostly industrial scale laboratories. Methamphetamine has begun moving into the gap the amphetamine trade left behind. It has taken root in Saudi Arabia and become a leading concern for treatment services in Iraq and Turkiye.

Treatment access lags behind the global drug crisis

Perhaps the starkest figure in the entire report concerns care rather than chemistry. Of the 63 million people living with drug use disorders worldwide, only one in twelve received any form of treatment in 2024. The gap is worse for women. Just one in twenty three accessed treatment, compared with one in nine men. Evidence shows women tend to progress from first use to dependence more quickly.

The report points to several barriers keeping people from recovery. These include high treatment costs, chronic staff and funding shortages, long waiting lists and persistent stigma. Meanwhile, coverage is thinnest in Africa and Asia, where the population affected by drug use is also youngest.

Access to essential pain relief remains sharply unequal too. Countries that account for nearly 80 per cent of the world’s serious health related suffering receive very little in return. Just 14 per cent of the world’s pharmaceutical opioids reach them, leaving huge numbers of patients without adequate palliative care.

Juma acknowledged that the figures assembled in Vienna cannot capture everything happening on the ground. Much of the data depends on what governments choose to report. Even so, she said the overall message was unmistakable. The world drug problem is evolving faster than the systems built to respond to it. Closing that gap, she argued, will depend on expanding prevention aimed at young people. It also requires stronger early intervention and genuine pathways into recovery for those already affected.

“Only by combining public health, justice and security approaches can we reduce harm, save lives and build safer, healthier and more resilient societies,” Juma wrote.

Source: dbrecoveryresources